We would like to show you a description here but the site won’t allow us.

Ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) is Adverum’s clinical-stage gene therapy product candidate being developed for the treatment of wet AMD.

Dec 8, 2025 · Get the latest Adverum Biotechnologies, Inc. (ADVM) stock price with news, financials and other important investing information.

Upon acquiring Annapurna Therapeutics and changing its name to Adverum Biotechnologies in May 2016, [8] it also changed its ticker symbol on Nasdaq from AAVL to ADVM.

Get real-time Adverum Biotechnologies Inc (ADVM) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

Dec 8, 2025 · REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal …

Eli Lilly (NYSE: LLY) to acquire Adverum Biotechnologies (NASDAQ: ADVM), including its lead product candidate, Ixo-vec, it said on Friday.

Mar 19, 2026 · Adverum Biotechnologies is a clinical-stage gene therapy company focused on the discovery, development and delivery of novel treatments for ocular and rare diseases.

Dec 9, 2025 · Webull offers Adverum Biotech stock information, including NASDAQ: ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, …

View live Adverum Biotechnologies, Inc. chart to track its stock's price action. Find market predictions, ADVM financials and market news.